Catalyst Pharmaceuticals Inc

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company dedicated to acquiring, developing, and marketing therapies for individuals with rare and challenging medical conditions. The company currently offers three marketed treatments: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Kalkine’s Diversified Opportunities Report covers the Company Overview, Key positives & negatives, Investment summary, Key investment metrics, Top 10 shareholding, Business updates and insights into company recent financial results, Key Risks & Outlook, Price performance and technical summary, Target Price, and Recommendation on the stock.

Stock Performance:

• The stock showed a strong uptrend from August to mid-November 2024, reaching highs around USD 25.
• The 21-day MA (USD 21.42) is below the 50-day MA (USD 23.12) — a bearish crossover that confirms short-term weakness. Price is currently hovering just above the 21-day MA and slightly below the 50-day MA, suggesting possible near-term resistance.
• RSI is at 46, hovering near neutral levels (30–70). This suggests no extreme momentum, but leans slightly toward bearish territory.               

1.2 The Key Positives, Negatives, and Investment summary

1.3 Top 10 shareholders:

The top 10 shareholders together form ~ 40.95% of the total shareholding, signifying concentrated shareholding. The BlackRock Institutional Trust Company, N.A. and The Vanguard Group, Inc. are the biggest shareholders, holding the maximum stake in the company at 13.46% and 6.95%, respectively.

1.4 Key Metrics:

The chart highlights Catalyst Pharmaceuticals’ strong financial improvement from Q1 FY24 to Q1 FY25, with significant gains across all profitability metrics. While the gross margin remained steady at a high 87.3%, substantial increases were observed in EBITDA margin (from 37.1% to 51.5%) and operating margin (from 27.5% to 44.8%), reflecting effective cost control and operating leverage. Income before tax and net margins also rose sharply, supported by robust revenue growth, particularly from AGAMREE’s full-quarter contribution and sustained demand for FIRDAPSE and FYCOMPA. Return on equity improved from 4.9% to 7.5%, indicating stronger shareholder value creation driven by higher net income and efficient capital use.

Section 2: Business Updates and Corporate Business Highlights

2.1 Recent Business Updates

2.2 Insights of Q1FY25:

Section 3: Key Risks & Outlook

Section 4: Stock Recommendation Summary:

4.1 Price Performance and Technical Summary:

Stock Performance:

• The stock showed a strong uptrend from August to mid-November 2024, reaching highs around USD 25.
• The 21-day MA (USD 21.42) is below the 50-day MA (USD 23.12) — a bearish crossover that confirms short-term weakness. Price is currently hovering just above the 21-day MA and slightly below the 50-day MA, suggesting possible near-term resistance.
• RSI is at 46, hovering near neutral levels (30–70). This suggests no extreme momentum, but leans slightly toward bearish territory.

4.2 Fundamental Valuation

Valuation Methodology: Price/Earnings per share Multiple Based Relative Valuation

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is July 23, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

 Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

 Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.